111(US:YI) Jin Rong Jie·2025-08-14 15:02Core Viewpoint - 1药网 (YI) is experiencing a slight increase in stock price, with financial data indicating a modest revenue growth but a significant decline in net profit [1][2]. Financial Performance - As of March 31, 2025, 1药网 reported total revenue of 3.529 billion RMB, reflecting a year-on-year growth of 0.02% [1]. - The company's net profit attributable to shareholders was -17.649 million RMB, showing a year-on-year decrease of 28.12% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, establishing itself as the largest healthcare platform in China [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model [2]. - The company went public on NASDAQ in 2018, becoming the first Chinese internet healthcare company to list in the U.S. [2].